Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

• Status: Terminated
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Solvay Pharmaceuticals
• Collaborators: H. Lundbeck A/S; Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Diagnosis of Schizophrenia

• 18-65 years

• No hospitalization for an exacerbation of schizophrenia within two months prior to screening and during the screening period

Exclusion Criteria:

• Subjects who are acutely psychotic or subjects with current Axis I primary psychiatric diagnosis other than schizophrenia

• At significant risk of suicide, and the potential for violent behavior (likely to harm themselves or others) based on history